AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- Researchers in Germany are trying "to identify as many candidates as possible for tumor-associated T-cell epitopes in individual patients."
According to T. Weinschenk and colleagues, University of Tubingen, "First, we performed expression profiling of tumor and normal tissue to identify genes exclusively expressed or overexpressed in the tumor sample. Then, using mass spectrometry, we characterized up to 77 different MHC [major histocompatibility complex] ligands from the same tumor sample.
"Several of the MHC ligands were derived from overexpressed gene products, one was derived from a proto-oncogene, and another was derived from a frameshift mutation. At least one was identified as an actual T-cell epitope," reported the researchers.
Weinschenk and colleagues concluded: "Thus, we could show that by combining these two analytic tools, it is possible to propose several candidates for peptide-based ...
Source: HighBeam Research, New approach helps identify peptide-based immunotherapeutics.